Literature DB >> 17145893

Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.

Gretchen E Lyons1, Tamson Moore, Natasha Brasic, Mingli Li, Jeffrey J Roszkowski, Michael I Nishimura.   

Abstract

The CD8 coreceptor on T cells has two functions. Namely, CD8 acts to stabilize the binding of the T-cell receptor (TCR) to the peptide-MHC complex while localizing p56(lck) (lck) to the TCR/CD3 complex to facilitate early signaling events. Although both functions may be critical for efficient activation of a CTL, little is known about how the structural versus signaling roles of CD8, together with the relative strength of the TCR, influences T-cell function. We have addressed these issues by introducing full-length and truncated versions of the CD8alpha and CD8beta chains into CD8(-) Jurkat cell clones expressing cloned TCRs with known antigen specificity and relative affinities. Using a combination of antigen recognition and tetramer-binding assays, we find that the intracellular lck-binding domain of CD8 is critical for enhanced T-cell activation regardless of the relative strength of the TCR. In contrast, the extracellular domain of CD8 seems to be critical for TCRs with lower affinity but not those with higher affinity. Based on our results, we conclude that there are different requirements for CD8 to enhance T-cell function depending on the strength of its TCR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145893     DOI: 10.1158/0008-5472.CAN-06-2379

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

2.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

3.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

4.  MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Authors:  Swagatam Ray; Arvind Chhabra; Nitya G Chakraborty; Upendra Hegde; David I Dorsky; Thinle Chodon; Erika von Euw; Begonya Comin-Anduix; Richard C Koya; Antoni Ribas; James S Economou; Steven A Rosenberg; Bijay Mukherji
Journal:  Clin Immunol       Date:  2010-05-23       Impact factor: 3.969

5.  CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.

Authors:  Andrew Zloza; Michael C Jagoda; Gretchen E Lyons; Michael C Graves; Frederick J Kohlhapp; Jeremy A O'Sullivan; Andrew T Lacek; Michael I Nishimura; José A Guevara-Patiño
Journal:  Cancer Immunol Immunother       Date:  2010-12-31       Impact factor: 6.968

6.  Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Authors:  Timothy T Spear; Yuan Wang; Thomas W Smith; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

7.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

8.  TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Authors:  Timothy T Spear; Kendra C Foley; Elizabeth Garrett-Mayer; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2018-01-19       Impact factor: 4.962

9.  Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.

Authors:  Simon Voelkl; Tamson V Moore; Michael Rehli; Michael I Nishimura; Andreas Mackensen; Karin Fischer
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

10.  Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Authors:  Tamson V Moore; Gretchen E Lyons; Natasha Brasic; Jeffrey J Roszkowski; Simon Voelkl; Andreas Mackensen; W Martin Kast; I Caroline Le Poole; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.